Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart
MWN-AI** Summary
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL), a late-stage life sciences company, is making significant strides in developing anti-inflammatory and anti-fibrotic therapies aimed at heart disease. The company is set to engage in a live interview with Barchart today at 12:00 PM EDT, where CEO David Elsley will discuss notable initiatives, including the ongoing Phase III MAVERIC trial and the recently published results from the Phase II ARCHER trial.
The MAVERIC program is pivotal for Cardiol, focusing on the lead candidate CardiolRx™, which addresses recurrent pericarditis—a condition marked by debilitating chest pain and fatigue that can severely hinder quality of life. The trial aims to evaluate the drug’s efficacy for patients affected by this inflammatory disease. Notably, CardiolRx™ has already received Orphan Drug Designation by the U.S. FDA, highlighting its potential significance in treating this condition.
Additionally, the ARCHER program is key in examining CardiolRx™ in acute myocarditis, a primary cause of sudden cardiac death in younger individuals. The completed Phase II ARCHER study assesses the drug's safety, tolerability, and efficacy in this vulnerable demographic.
Beyond CardiolRx™, the company is also pioneering CRD-38, an innovative subcutaneously administered drug formulation targeting inflammatory heart diseases, particularly heart failure. Given that heart failure poses a critical health burden with substantial economic implications, the development of CRD-38 could represent an important advance in treatment options.
Investors and stakeholders are encouraged to follow the live interview and check Cardiol’s channels post-event for insights into the company’s future direction in the landscape of heart disease therapies. For additional information, visit cardiolrx.com.
MWN-AI** Analysis
As Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL) gears up for a live interview with Barchart, investors should keenly focus on the progress of its MAVERIC Phase III trial and the recently published results from the ARCHER Phase II trial. Both studies are pivotal for Cardiol, targeting heart diseases with high unmet medical needs.
The ongoing MAVERIC trial is evaluating CardiolRx™ for recurrent pericarditis, a debilitating condition that significantly affects patients' quality of life. Given the FDA's Orphan Drug Designation for CardiolRx™, the potential for regulatory support increases, making this a critical phase for the drug's market entry. Investors might view this as a strong validation of Cardiol's innovation in a niche market that could yield both revenue and broader clinical implications.
Meanwhile, insights from the ARCHER trial bolster investor confidence by exploring CardiolRx™’s efficacy in acute myocarditis—an area with limited treatment options. Its safety and tolerability profile, combined with the demonstration of efficacy in this younger patient demographic, positions Cardiol favorably within the cardiology market, attracting potential collaborations or partnerships.
Additionally, CRD-38, Cardiol's next-generation formulation, aims to target inflammatory heart disease more broadly, including heart failure, a leading cause of mortality globally. The development of CRD-38 could extend the company’s reach within critical therapeutic areas, diversifying its portfolio and ensuring sustained interest from investors.
In light of these developments, investors should approach Cardiol Therapeutics with a nuanced understanding, weighing the potential market impact of clinical results against inherent risks in drug development. This balance of optimism and caution will be vital as updates from the MAVERIC trial and future data from the ARCHER program unfold.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Toronto, Ontario--(Newsfile Corp. - April 14, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that Cardiol's President and Chief Executive Officer, David Elsley, will participate in a live interview on X with Barchart.com ("Barchart") today at 12:00 p.m. EDT.
Interview Topics:
- The ongoing pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis
- Results from the recently published Phase II ARCHER trial of CardiolRx™ in acute myocarditis
- The Company's next generation drug, CRD-38, in development for heart failure
Interview details:
Date: April 14, 2026
Time: 12:00 PM EDT
Platform: X
Host Account on X: @Barchart
Join Live Interview at: x.com/Barchart
After the event, a full recording of the interview will be available on the Company's X channel (@CardiolRx) and Barchart's (@Barchart).
About Cardiol Therapeutics
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.
The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis.
The ARCHER Program is also studying CardiolRx™, specifically in acute myocarditis—an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed Phase II ARCHER study (NCT05180240), which evaluated the safety, tolerability, and efficacy of CardiolRx™ in this patient population.
The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure—a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion per year.
For more information about Cardiol Therapeutics, please visit cardiolrx.com.
Cautionary statement regarding forward-looking information:
This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are "forward-looking information". Forward-looking information contained herein may include, but is not limited to statements regarding the Company's focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease; the Company's intended clinical studies and trial activities and timelines associated with such activities, including the Company's plan to complete the Phase III study in recurrent pericarditis with CardiolRx™; the Company's plan to advance the development of CRD-38, a novel subcutaneous formulation intended for the treatment of inflammatory heart disease, including heart failure. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2026, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements.
For further information, please contact:
Investor.relations@cardiolrx.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/292336
FAQ**
How is Cardiol Therapeutics Inc. (CRDL) advancing its pivotal Phase III MAVERIC trial and what does it mean for the future of recurrent pericarditis treatment in Toronto, Ontario?
What recent findings from the Phase II ARCHER trial of CardiolRx™ in acute myocarditis have been discussed by Cardiol Therapeutics Inc. (CRDL) and their implications for heart disease management?
In what ways is Cardiol Therapeutics Inc. (CRDL) planning to develop its next-generation drug CRD-38, and how might it impact the treatment landscape for heart failure in Toronto, Ontario?
Given the Orphan Drug Designation awarded to CardiolRx™ by the U.S. FDA, how does Cardiol Therapeutics Inc. (CRDL) envision leveraging this status to benefit patients in Toronto who suffer from pericarditis?
**MWN-AI FAQ is based on asking OpenAI questions about Cardiol Therapeutics Inc. (NASDAQ: CRDL).
NASDAQ: CRDL
CRDL Trading
-2.96% G/L:
$1.965 Last:
1,077,378 Volume:
$2.03 Open:
CRDL Latest News
